These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39039387)

  • 1. Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study.
    Cao G; Yang H; Wang J; Ishida M; Thoma C; Haeufel T; Bossert S; Zhang J
    Adv Ther; 2024 Sep; 41(9):3557-3568. PubMed ID: 39039387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Spesolimab for Generalized Pustular Psoriasis.
    Bachelez H; Choon SE; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Anadkat MJ; Rajeswari S; Hua H; Vulcu SD; Hall D; Tetzlaff K; Thoma C; Lebwohl MG;
    N Engl J Med; 2021 Dec; 385(26):2431-2440. PubMed ID: 34936739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies.
    Joseph D; Thoma C; Haeufel T; Li X
    Clin Pharmacokinet; 2022 Dec; 61(12):1771-1787. PubMed ID: 36451029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval.
    Gwillim EC; Nichols AJ
    Front Immunol; 2024; 15():1359481. PubMed ID: 39104539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial.
    Tsai TF; Zheng M; Ding Y; Song Z; Liu Q; Chen Y; Hu H; Xu J
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):3097-3110. PubMed ID: 37840119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
    Morita A; Choon SE; Bachelez H; Anadkat MJ; Marrakchi S; Zheng M; Tsai TF; Turki H; Hua H; Rajeswari S; Thoma C; Burden AD
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):347-359. PubMed ID: 36333618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
    Morita A; Strober B; Burden AD; Choon SE; Anadkat MJ; Marrakchi S; Tsai TF; Gordon KB; Thaçi D; Zheng M; Hu N; Haeufel T; Thoma C; Lebwohl MG
    Lancet; 2023 Oct; 402(10412):1541-1551. PubMed ID: 37738999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
    Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
    J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spevigo® (Spesolimab-Sbzo) Injection for the Treatment of Generalized Pustular Psoriasis.
    Gupta AK; Mann A; Vincent K; Abramovits W
    Skinmed; 2024; 22(2):134-137. PubMed ID: 39089999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Pharmacokinetics of Single-Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study.
    Xu J; Xie R; Ji Y; Qian C; Zhang X; Todd K; Wang F; Cui Y
    Clin Pharmacol Drug Dev; 2024 Oct; 13(10):1143-1150. PubMed ID: 39230208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study.
    Meng X; Wang Q; Wu S; Pu D; Zhang A; Fang S; Zhou X; Lu H
    Rheumatol Ther; 2021 Dec; 8(4):1711-1724. PubMed ID: 34554352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies.
    Dong Z; Hashizume K; Friedrichs F; Liu P; Tanaka T; Liao Y
    Pharmacol Res Perspect; 2024 Oct; 12(5):e70012. PubMed ID: 39308062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
    Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
    Morita A; Tsai TF; Yee EYW; Okubo Y; Imafuku S; Zheng M; Li L; Quaresma M; Thoma C; Choon SE
    J Dermatol; 2023 Feb; 50(2):183-194. PubMed ID: 36282833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
    Zhu Y; Wang Q; Frederick B; Bouman-Thio E; Marini JC; Keen M; Petty KJ; Davis HM; Zhou H
    Clin Drug Investig; 2013 Apr; 33(4):291-301. PubMed ID: 23512638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
    Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
    J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants.
    Li Y; Zhang H; Pandya H; Miao L; Reid F; Jimenez E; Sadiq MW; Moate R; Lei A; Zhou XH; Kell C; Ding J; Zhang G; Zhao L; Ge X
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):665-671. PubMed ID: 38523487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis.
    Pathak GN; Wang E; Dhillon J; Parikh PN; Esseghir R; Rao BK; Feldman SR
    Ann Pharmacother; 2024 May; ():10600280241252688. PubMed ID: 38755971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.
    Papp KA; Gooderham MJ; Girard G; Raman M; Strout V
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1324-1332. PubMed ID: 28556418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.